Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain Capital-led financing as part of the Big Pharma’s ambitious cost-cutting drive.

While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb ...

Details on a BMS based on electrochemical impedance spectroscopy (EIS). BMS advances to keep pace with EV rising complexity. Building better battery models based on EIS characterization. The ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...

Battery-powered applications, which have become indispensable over the last decade, require a certain level of protection to ensure safe use. This safety is provided by the battery management system ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

A battery management system (BMS) monitors and controls batteries in vehicles such as more-electric aircraft and electric cars. It needs to undergo rigorous tests under nominal and extreme conditions ...

Bayer announced that it is halting a late-stage trial for asundexian, a high-profile candidate for cardiovascular disease. Bristol Myers Squibb and Johnson & Johnson are co-developing a therapy that ...

Bristol Myers Squibb (BMS) (NYSE: BMY), a multinational pharmaceutical company, has all the hallmarks of a top-shelf dividend stock. The company has boosted its dividend for 14 consecutive years, has ...

The uncertainty created by its upcoming leadership change and ongoing portfolio churn has kept investors at bay this year. However, there are several solid reasons to consider buying this ...